A high proportion of tumours have the ability to avoid detection and destruction by the immune system. These immunologically “cold” cancers are hard to detect and show little response to conventional treatments.
Everyday is a struggle for patients fighting cancer. Our commitment is to develop new medicines that will make this struggle a thing of the past.
AT-101 could find utility in treating tumours with currently unmet clinical need, such as liver, bowel, or pancreatic cancer.
Protein methyltransferases (PRMTs) catalyse the methylation of target proteins and PRMT5 catalyses the symmetric dimethylation of proteins involved in a wide array of cellular processes including growth control, splicing, inflammation, immune response and metabolic processes.
The high levels of PRMT5 protein observed in many cancers and the correlation with poor prognosis makes PRMT5 a compelling anti-cancer target.
IngenOx has developed AT101, a highly potent and selective inhibitor of PRMT5, which has been designed for oral administration.
At IngenOX We've Developed AT-101: A Small Molecule Inhibitor of the Protein PRMT5.
AT101 selectively binds to PRMT5, and inhibits its function
This blocks the gene expression pathways required by cancer cells for growth and proliferation.
We have identified a group of biomarkers that correlate strongly with PRMT5-driven tumour response, which will enable us to target the AT101 to the right patients.
Cell replication is regulated by the transcription factor E2F1
In tumour cells, E2F1 exists in a liberated methylated state, where it drives uncontrolled cell proliferation. However, E2F1 can also promote cell suicide (apoptosis).
Switching E2F1 into cell death mode
This dual role of E2F1 in regulating cell proliferation and apoptosis is controlled by arginine methylation status. Inhibition of PRMT5-mediated arginine methylation by AT-101 switches E2F1 from its growth-promoting mode into cell death mode.
Cancer remains a devastating and clinically unmet disease. Our Mission at IngenOx Therapeutics is to fix this.
IngenOx Therapeutics, is a biopharma spin-out from Oxford University, committed to the progression of precision therapies and vaccines for many common cancers, with particular focus on those where there is still an unmet need for long-term disease control.
Our goal is to develop effective, personalised therapies, reduce side effects and improve the lives and outcomes of individuals and patients across the globe.
"The idea behind personalised cancer medicine is both simple and powerful: delivering the right treatment to the right patient at the right time. Our aim is to radically alter the way cancer is managed, saving lives by focusing on the individual"
David Kerr
CBE MA MSc MD PhD DSc FRCP FRCGP FACP FMedSci
CMO IngenOx Therapeutics
News & Press
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Investment Opportunities
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi sollicitudin, tellus non luctus ullamcorper, tortor mauris laoreet.
Learn About Our Partners
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi sollicitudin, tellus non luctus ullamcorper, tortor mauris laoreet.